TRAF1 is involved in the classical NF-κB activation and CD30-induced alternative activity in Hodgkin's lymphoma cells

Molecular Immunology

Volumn 46, Issue 13, 2009, Pages 2441-2448

  Guo, Feng ^a   Sun, Aining ^b   Wang, Wenjuan ^b   He, Jun ^b   Hou, Jianquan ^a   Zhou, Peng ^a   Chen, Zixing ^b  

^a SOOCHOW UNIVERSITY   (China)

^b Jiangsu Institute of Hematology   (China)

Author keywords

Lymphoma; NF B; siRNA; TRAF1

Indexed keywords

CD30 ANTIGEN; CYCLIN D1; FLICE INHIBITORY PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; MITOGEN ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 5;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; HODGKIN DISEASE; HUMAN; HUMAN CELL; LYMPHOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UPREGULATION;

ANTIGENS, CD30; APOPTOSIS; B-LYMPHOCYTES; BLOTTING, WESTERN; CELL LINE, TUMOR; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION, NEOPLASTIC; HODGKIN DISEASE; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TNF RECEPTOR-ASSOCIATED FACTOR 1; TNF RECEPTOR-ASSOCIATED FACTOR 5;

EID: 67650388511     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2009.05.178     Document Type: Article

References (44)

1. Al-Shamkhani A. The role of CD30 in the pathogenesis of haematopoietic malignancies. Curr. Opin. Pharmacol. 4 (2004) 355-359
2. Baker S., and Reddy E. Modulation of life and death by the TNF receptor superfamily. Oncogene 17 (1998) 3261-3270
3. Bargou R.C., Emmerich F., Krappmann D., Bommert K., Mapara M.Y., Arnold W., Royer H.D., Grinstein E., Greiner A., Scheidereit C., and Dorken B. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J. Clin. Invest. 100 (1997) 2961-2969
4. Bishop G., Moore C., Xie P., Stunz L., and Kraus Z. TRAF proteins in CD40 signaling. Adv. Exp. Med. Biol. 597 (2007) 131-151
5. Boucher L.M., Marengère L.E., Lu Y., Thukral S., and Mak T.W. Binding sites of cytoplasmic effectors TRAF1, 2, and 3 on CD30 and other members of the TNF receptor superfamily. Biochem. Biophys. Res. Commun. 28 (1997) 592-600
6. Bradley J.R., and Pober J.S. Tumor necrosis factor receptor-associated factors (TRAFs). Oncogene 20 (2001) 6482-6491
7. Darnay B., Besse A., Poblenz A., Lamothe B., and Jacoby J. TRAFs in RANK signaling. Adv. Exp. Med. Biol. 597 (2007) 152-159
8. Duckett C., and Thompson C. CD30-dependent degradation of TRAF2: implications for negative regulation of TRAF signaling and the control of cell survival. Genes Dev. 11 (1997) 2810-2821
9. Dürkop H., Latza U., Hummel M., Eitelbach F., Seed B., and Stein H. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 68 (1992) 421-427
10. Dürkop H., Foss H., Demel G., Klotzbach H., Hahn C., and Stein H. Tumor necrosis factor receptor-associated factor 1 is overexpressed in Reed-Sternberg cells of Hodgkin's disease and Epstein-Barr virus-transformed lymphoid cells. Blood 93 (1999) 617-623
11. Dürkop H., Hirsch B., Hahn C., Foss H., and Stein H. Differential expression and function of A20 and TRAF1 in Hodgkin lymphoma and anaplastic large cell lymphoma and their induction by CD30 stimulation. J. Pathol. 200 (2003) 229-239
12. Falini B., Venturi S., Martélli M., Santucci A., Pileri S., Pescarmona E., Giovannini M., Mazza P., Martelli M.F., and Pasqualucci L. Mediastinal large B-cell lymphoma: clinical and immunohistological findings in 18 patients treated with different third-generation regimens. Br. J. Haematol. 89 (1995) 780-789
13. Galibert L., Tometsko M., Anderson D., Cosman D., and Dougall W. The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-kappaB, a member of the TNFR superfamily. J. Biol. Chem. 273 (1998) 34120-34127
14. Gedrich R., Gilfillan M., Duckett C., Van Dongen J., and Thompson C. CD30 contains two binding sites with different specificities for members of the tumor necrosis factor receptor-associated factor family of signal transducing proteins. J. Biol. Chem. 271 (1996) 12852-12858
15. Gruss H.J., and Kadin M.E. Pathophysiology of Hodgkin's disease: functional and molecular aspects. Baillieres Clin. Haematol. 9 (1996) 417-446
16. Guo F., Weih D., Meier E., and Weih F. Constitutive alternative NF-kappaB signaling promotes marginal zone B-cell development but disrupts the marginal sinus and induces HEV-like structures in the spleen. Blood 110 (2007) 2381-2389
17. Guo F., Tänzer S., Busslinger M., and Weih F. Lack of nuclear factor-kappa B2/p100 causes a RelB-dependent block in early B lymphopoiesis. Blood 112 (2008) 551-559
18. Hatzoglou A., Roussel J., and Bourgeade M. TNF receptor family member BCMA (B cell maturation) associates with TNF receptor-associated factor (TRAF) 1, TRAF2, and TRAF3 and activates NF-kappa B, elk-1, c-Jun N-terminal kinase, and p38 mitogen-activated protein kinase. J. Immunol. 165 (2000) 1322-1330
19. He J.Q., Zarnegar B., Oganesyan G., Saha S.K., Yamazaki S., Doyle S.E., Dempsey P.W., and Cheng G. Rescue of TRAF3-null mice by p100 NF-kappa B deficiency. J. Exp. Med. 203 (2006) 2413-2418
20. Hinz M., Löser P., Mathas S., Krappmann D., Dörken B., and Scheidereit C. Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells. Blood 97 (2001) 2798-2807
21. Hirsch B., Hummel M., Bentink S., Fouladi F., Spang R., Zollinger R., Stein H., and Dürkop H. CD30-induced signaling is absent in Hodgkin's cells but present in anaplastic large cell lymphoma cells. Am. J. Pathol. 172 (2008) 510-520
22. Horie R., Aizawa S., Nagai M., Ito K., Higashihara M., Ishida T., Inoue J., and Watanabe T. A novel domain in the CD30 cytoplasmic tail mediates NFkappaB activation. Int. Immunol. 10 (1998) 203-210
23. Horie R., and Watanabe T. CD30: expression and function in health and disease. Semin. Immunol. 10 (1998) 457-470
24. Horie R., Watanabe T., Morishita Y., Ito K., Ishida T., Kanegae Y., Saito I., Higashihara M., Mori S., Kadin M.E., and Watanabe T. Ligand-independent signaling by overexpressed CD30 drives NF-kappaB activation in Hodgkin-Reed-Sternberg cells. Oncogene 11 (2002) 2493-2503
25. Horie R., and Watanabe T. The biological basis of Hodgkin's lymphoma. Drug News Perspect. 16 (2003) 649-656
26. Kaye K., Devergne O., and Harada J. Tumor necrosis factor receptor associated factor 2 is a mediator of NF-kappa B activation by latent infection membrane protein 1, the Epstein-Barr virus transforming protein. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 11085-11090
27. Izban K.F., Ergin M., Martinez R.L., and Alkan S. Expression of the tumor necrosis factor receptor-associated factors (TRAFs) 1 and 2 is a characteristic feature of Hodgkin and Reed-Sternberg cells. Mod. Pathol. 13 (2000) 1324-1331
28. Lee S., Kandala G., Liou M., Liou H., and Choi Y. CD30/TNF receptor-associated factor interaction: NF-kappaB activation and binding specificity. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 9699-9703
29. Lee S., and Choi Y. TRAF1 and its biological functions. Adv. Exp. Med. Biol. 597 (2007) 25-31
30. Marafioti T., Hummel M., Foss H.D., Laumen H., Korbjuhn P., Anagnostopoulos I., Lammert H., Demel G., Theil J., Wirth T., and Stein H. Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood 95 (2000) 1443-1450
31. Munzert G., Kirchner D., Stobbe H., Bergmann L., Schmid R.M., Döhner H., and Heimpel H. Tumor necrosis factor receptor-associated factor 1 gene overexpression in B-cell chronic lymphocytic leukemia: analysis of NF-kappa B/Rel-regulated inhibitors of apoptosis. Blood 15 (2002) 3749-3756
32. Nonaka M., Horie R., Itoh K., Watanabe T., Yamamoto N., and Yamaoka S. Aberrant NF-kappaB2/p52 expression in Hodgkin/Reed-Sternberg cells and CD30-transformed rat fibroblasts. Oncogene 24 (2005) 3976-3986
33. Pullen S., Miller H., Everdeen D., Dang T., Crute J., and Kehry M. CD40-tumor necrosis factor receptor-associated factor (TRAF) interactions: regulation of CD40 signaling through multiple TRAF binding sites and TRAF hetero-oligomerization. Biochemistry 37 (1998) 11836-11845
34. Saitoh Y., Yamamoto N., Dewan M.Z., Sugimoto H., Martinez Bruyn V.J., Iwasaki Y., Matsubara K., Qi X., Saitoh T., Imoto I., Inazawa J., Utsunomiya A., Watanabe T., Masuda T., Yamamoto N., and Yamaoka S. Overexpressed NF-kappaB-inducing kinase contributes to the tumorigenesis of adult T-cell leukemia and Hodgkin Reed-Sternberg cells. Blood 111 (2008) 5118-5129
35. Siegel R., Muppidi J., Roberts M., Porter M., and Wu Z. Death receptor signaling and autoimmunity. Immunol. Res. 27 (2003) 499-512
36. Speiser D.E., Lee S.Y., Wong B., Arron J., Santana A., Kong Y.Y., Ohashi P.S., and Choi Y. A regulatory role for TRAF1 in antigen-induced apoptosis of T cells. J Exp Med. 185 (1997) 1777-1783
37. Weih F., and Caamaño J. Regulation of secondary lymphoid organ development by the nuclear factor-kappaB signal transduction pathway. Immunol. Rev. 195 (2003) 91-105
38. Wong B., Josien R., Lee S., Vologodskaia M., Steinman R., and Choi Y. The TRAF family of signal transducers mediates NF-kappaB activation by the TRANCE receptor. J. Biol. Chem. 273 (1998) 28355-28359
39. Wright C.W., Rumblem J.M., and Duckett C.S. CD30 activates both the canonical and alternative NF-kappaB pathways in anaplastic large cell lymphoma cells. J. Biol. Chem. 6 (2007) 10252-10262
40. Xie P., and Bishop G. Roles of TNF receptor-associated factor 3 in signaling to B lymphocytes by carboxyl-terminal activating regions 1 and 2 of the EBV-encoded oncoprotein latent membrane protein 1. J. Immunol. 173 (2004) 5546-5555
41. Yilmaz Z., Weih D., Sivakumar V., and Weih F. RelB is required for Peyer's patch development: differential regulation of p52-RelB by lymphotoxin and TNF. EMBO J. 22 (2003) 121-130
42. Zapata J.M., Krajewska M., Krajewski S., Kitada S., Welsh K., Monks A., McCloskey N., Gordon J., Kipps T.J., Gascoyne R.D., Shabaik A., and Reed J.C. TNFR-associated factor family protein expression in normal tissues and lymphoid malignancies. J. Immunol. 165 (2000) 5084-5096
43. Zapata J.M., Krajewska M., Morse Hr., Choi Y., and Reed J.C. TNF receptor-associated factor (TRAF) domain and Bcl-2 cooperate to induce small B cell lymphoma/chronic lymphocytic leukemia in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 16600-16605
44. Zheng B., Fiumara P., Li Y.V., Georgakis G., Snell V., Younes M., Vauthey J.N., Carbone A., and Younes A. MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. Blood 102 (2003) 1019-1027